Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2021-A00134-37 | Other Identifier | 2021-A00134-37 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
By 2050, the expanding world population will consume two-thirds more animal protein than it consumes today. The increase in chronic diseases associated with the generalization of these consumption patterns tend to understand the place of meat in our diets. All these elements participate to the reduction of animal proteins in favor of vegetable proteins in our food. The elderly are particularly affected by malnutrition, the prevalence of protein-energy malnutrition increasing with age and promoting the onset of morbidities. Without care, it leads to the worsening of physiological phenomena linked to aging such as loss of muscle functionality (sarcopenia) or reduction in bone density (osteoporosis) and increases the risk of falls - the main cause of dependence. However, in France, protein consumption declines significantly with age, even though requirements appear to be greater for the elderly. It is therefore a major challenge for our societies to ensure that the aging of the population and the increase in life expectancy are not synonymous with a reduction in the physical and mental capacities of individuals. Thus, it is essential to ensure that the recommendations for reducing the intake of animal proteins in favor of vegetable proteins can be applied without risk to aging populations, in particular on the human body cardiovascular risk of these populations.
This human dietary intervention study is a double blind, randomized, placebo controlled, cross over trial with 3 arms, carried out on subjects with predisposition to cardiometabolic syndrome (based on weight circumference, blood triglyceride or blood cholesterol, glycemia and hypertension). This study aims to demonstrate transient improvement in vascular endothelial function (with Flow Mediated Dilatation (FMD) as main criteria) with consumption of vegetable proteins (rich in leucine, cysteine and arginine) by comparison with animal proteins and with a control without proteins.
The 33 recruited participants will receive the 3 yogurts in a random order. For each subject, the study is divided into 4 visits.
To summarize: Visit 1 (D-7) = inclusion, Visit 2 (D0: treatment period N°1), Visit 3 (D28 : treatment period N°2), Visit 4 (D56 : treatment period N°3). The wash-out periods between treatment period (duration: 4 weeks) may be extended until 5 weeks for the convenience of participants.
The protocol includes a total of 4 visits to PIC/CIC Inserm 1405 of the Clermont-Fd University Hospital.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group/Cohort1 | Experimental | 33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt rich in cysteine, leucine and arginine (VP, vegetable proteins) only once during the visit |
|
| Group/Cohort2 | Experimental | 33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt rich in animal proteins (AP) only once during the visit |
|
| Group/Cohort3 | Placebo Comparator | 33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt without any proteins (T) only once during the visit |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vegetable proteins (VP) rich in leucine, cystein, arginine | Behavioral | 33 volunteers will consume 400 ml of yogurt with vegetable proteins (VP) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of vegetable proteins. |
| Measure | Description | Time Frame |
|---|---|---|
| Brachial artery Flow Mediated Dilation (FMD) | The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized. | Day 0 (V1) at T-30min |
| Brachial artery Flow Mediated Dilation (FMD) | The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized between T-30min to T300min. | Day 0 (V1) at T180min |
| Brachial artery Flow Mediated Dilation (FMD) | The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized between T-30min to T300min. | Day 0 (V1) at T300min |
| Brachial artery Flow Mediated Dilation (FMD) | The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized between T-30min to T300min. | Day 28 (V2) at T-30min |
| Brachial artery Flow Mediated Dilation (FMD) | The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized between T-30min to T300min. |
| Measure | Description | Time Frame |
|---|---|---|
| Rest flow by Flowmetry Laser Doppler (FLD) | Vascular endothelial function in the micro-vascular compartment will be assessed using the measurement of the rest flow using laser-Doppler system at the level of the skin of the hand realized between T-30min to T300min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Occlusion area by FLD |
Not provided
Inclusion Criteria:
Man or woman
65 years old and older (inclusive)
At least 2 of the following 4 cardiometabolic factors:
Accept not to change his lifestyle throughout the study
Accept to consume the same meal the day before exploration days, making sure to exclude non-recommended foods and agreeing to detail its content in a food diary
Ability to give informed consent to participate in research
Affiliation to Social Security
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gisèle PICKERING | University Hospital, Clermont-Ferrand | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU clermont-ferrand | Clermont-Ferrand | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39424070 | Derived | Dimina LJ, Leray V, Voute M, David J, Blavignac C, Farges MC, Rossary A, Tsikas D, Remond D, Pickering G, Mariotti F. Dietary Protein in a Challenge Meal Does Not Alleviate Postprandial Impairments in Vascular Endothelial Function in Healthy Older Adults with Cardiometabolic Risk: A Randomized Crossover-Controlled Trial. J Nutr. 2024 Dec;154(12):3664-3680. doi: 10.1016/j.tjnut.2024.10.018. Epub 2024 Oct 16. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Product kit (yogurt) will be labelled and packaged according to the pre-established randomization plane by the pharmacy department of University Hospital of Clermont-Ferrand, France. Kits will be distributed in a blind fashion for each cross over period on the basis of the randomization schedule.
|
| Animal proteins (AP) | Behavioral | 33 volunteers will consume 400 ml of yogurt with animal proteins (AP) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of animal proteins. |
|
| No protein (T) | Behavioral | 33 volunteers will consume 400 ml of yogurt without any protein (T) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of animal proteins. |
|
| Day 28 (V2) at T180min |
| Brachial artery Flow Mediated Dilation (FMD) | The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized between T-30min to T300min. | Day 28 (V2) at T300min |
| Brachial artery Flow Mediated Dilation (FMD) | The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized between T-30min to T300min. | Day 56 (V3) at T-30min |
| Brachial artery Flow Mediated Dilation (FMD) | The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized between T-30min to T300min. | Day 56 (V3) at T180min |
| Brachial artery Flow Mediated Dilation (FMD) | The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized between T-30min to T300min. | Day 56 (V3) at T300min |
Vascular endothelial function in the micro-vascular compartment will be assessed using the measurement of the occlusion area using laser-Doppler system at the level of the skin of the hand by following the response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery (same stimulus as for FMD measurement) realized between T-30min to T300min. |
| Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Hyperaemia area by FLD | Vascular endothelial function in the micro-vascular compartment will be assessed using the measurement of the hyperaemia area using laser-Doppler system at the level of the skin of the hand by following the response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery (same stimulus as for FMD measurement) realized between T-30min to T300min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Hyperaemia area / occlusion area ratio by FLD | Vascular endothelial function in the micro-vascular compartment will be assessed using the ratio hyperaemia area / occlusion area determined by FLD realized between T-30min to T300min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Maximal flow by FLD | Vascular endothelial function in the micro-vascular compartment will be assessed using the measurement of the maximal flow using laser-Doppler system at the level of the skin of the hand by following the response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery (same stimulus as for FMD measurement) realized between T-30min to T300min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Hyperaemia half time by FLD | Vascular endothelial function in the micro-vascular compartment will be assessed using the measurement of the hyperaemia half time using laser-Doppler system at the level of the skin of the hand by following the response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery (same stimulus as for FMD measurement) realized between T-30min to T300min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Reactive Hyperemia - Peripheral Arterial Tonometry (RH-PAT) | Reactive hyperemia index (RHI) assessed by reactive hyperemia-peripheral arterial tonometry (RH-PAT) expressed as a percentage measures pulsatile fluctuations in digital volume in response to a reactive hyperaemia induced by the release of a transient occlusion realized between T-30min to T300min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Plasma nitrite dosage | Determination of nitrite plasma concentration (µmol/L) (a biomarker of endothelial activation) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Urine nitrite dosage | Determination of nitrite urine concentration (µmol/L) (a biomarker of endothelial activation) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Plasma nitrate dosage | Determination of nitrate plasma concentration (µmol/L) (a biomarker of endothelial activation) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Urine nitrate dosage | Determination of nitrate urine concentration (µmol/L) (a biomarker of endothelial activation) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Plasma creatinine dosage | Determination of creatinine plasma concentration (µmol/L) (a biomarker of chronic kidney disease) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Urine creatinine dosage | Determination of creatinine urine concentration (µmol/L) (a biomarker of chronic kidney disease) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Plasma malondialdehyde (MDA) dosage | Determination of MDA plasma concentration (nmol/L) (a biomarker of oxidative stress) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Urine malondialdehyde (MDA) dosage | Determination of MDA urine concentration (nmol/L) (a biomarker of oxidative stress) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Plasma asymmetric dimethylarginine (ADMA) dosage | Determination of ADMA plasma concentration (µmol/L) (a biomarker of cardiovascular disease) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Urine asymmetric dimethylarginine (ADMA) dosage | Determination of ADMA urine concentration (µmol/L) (a biomarker of cardiovascular disease) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Plasma symmetric dimethylarginine (SDMA) dosage | Determination of SDMA plasma concentration (µmol/L) (a biomarker of cardiovascular disease) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Urine symmetric dimethylarginine (SDMA) dosage | Determination of SDMA urine concentration (µmol/L) (a biomarker of cardiovascular disease) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Plasma acetyl-lysine dosage | Determination of acetyl-lysine plasma concentration (µmol/L) (a biomarker of vascular oxidative stress) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3) |
| Urine symmetric acetyl-lysine dosage | Determination of acetyl-lysine urine concentration (µmol/L) (a biomarker of vascular oxidative stress) between T-60min to T250min | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma N-epsilon-carboxy-methyl lysine (CML) dosage | Determination of CML plasma concentration (pg/mL) (a biomarker of oxidative stress) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine N-epsilon-carboxy-methyl lysine (CML) dosage | Determination of CML urine concentration (pg/mL) (a biomarker of oxidative stress) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma N-epsilon-carboxy-ethyl lysine (CEL) dosage | Determination of CEL plasma concentration (pg/mL) (a biomarker of oxidative stress) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine N-epsilon-carboxy-ethyl lysine (CEL) dosage | Determination of CEL urine concentration (pg/mL) (a biomarker of oxidative stress) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma alanine dosage | Determination of alanine plasma concentration (µmol/L) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine alanine dosage | Determination of alanine urine concentration (µmol/L) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma arginine dosage | Determination of arginine plasma concentration (µmol/L) between T-90min to T360min | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine arginine dosage | Determination of arginine urine concentration (µmol/L) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma asparagine dosage | Determination of asparagine plasma concentration (µmol/L) between T-90min to T360min | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine asparagine dosage | Determination of asparagine urine concentration (µmol/L) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma aspartic acid dosage | Determination of aspartic acid plasma concentration (µmol/L) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine aspartic acid dosage | Determination of aspartic acid urine concentration (µmol/L) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma cysteine dosage | Determination of cysteine plasma concentration (µmol/L) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine cysteine dosage | Determination of cysteine urine concentration (µmol/L) between T-60min to T250min | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma glutamic acid dosage | Determination of glutamic acid plasma concentration (µmol/L) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine glutamic acid dosage | Determination of glutamic acid urine concentration (µmol/L) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma glutamine dosage | Determination of glutamine plasma concentration (µmol/L) between T-90min to T360min | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine glutamine dosage | Determination of glutamine urine concentration (µmol/L) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma glycine dosage | Determination of glycine plasma concentration (µmol/L) between T-90min to T360min | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine glycine dosage | Determination of glycine urine concentration (µmol/L) between T-60min to T250min | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma histidine dosage | Determination of histidine plasma concentration (µmol/L) between T-90min to T360min | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine histidine dosage | Determination of histidine urine concentration (µmol/L) between T-60min to T250min | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma isoleucine dosage | Determination of isoleucine plasma concentration (µmol/L) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine isoleucine dosage | Determination of isoleucine urine concentration (µmol/L) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma leucine dosage | Determination of leucine plasma concentration (µmol/L) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine leucine dosage | Determination of leucine urine concentration (µmol/L) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma lysine dosage | Determination of lysine plasma concentration (µmol/L) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine lysine dosage | Determination of lysine urine concentration (µmol/L) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma methionine dosage | Determination of methionine plasma concentration (µmol/L) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine methionine dosage | Determination of methionine urine concentration (µmol/L) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma phenylalanine dosage | Determination of phenylalanine plasma concentration (µmol/L) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine phenylalanine dosage | Determination of phenylalanine urine concentration (µmol/L) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma proline dosage | Determination of proline plasma concentration (µmol/L) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine proline dosage | Determination of proline urine concentration (µmol/L) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma serine dosage | Determination of serine plasma concentration (µmol/L) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine serine dosage | Determination of serine urine concentration (µmol/L) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma threonine dosage | Determination of threonine plasma concentration (µmol/L) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine threonine dosage | Determination of threonine urine concentration (µmol/L) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma tryptophan dosage | Determination of tryptophan plasma concentration (µmol/L) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine tryptophan dosage | Determination of tryptophan urine concentration (µmol/L) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma tyrosine dosage | Determination of tyrosine plasma concentration (µmol/L) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine tyrosine dosage | Determination of tyrosine urine concentration (µmol/L) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma valine dosage | Determination of tyrosine plasma concentration (µmol/L) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Urine valine dosage | Determination of tyrosine urine concentration (µmol/L) between T-60min to T250min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma Interleukin 6 (IL-6) dosage | Determination of IL-6 plasma concentration (pg/ml) (a biomarker of inflammation and oxidative stress) between T-90min to T360min | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma Interleukin 1 bêta (IL-1β) dosage | Determination of IL-1β plasma concentration (pg/ml) (a biomarker of inflammation and oxidative stress) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma Monocyte Chemoattractant Protein-1 (MCP-1) dosage | Determination of MCP-1 plasma concentration (pg/ml) (a biomarker of inflammation and oxidative stress) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma Tumor Necrosis Factor alpha (TNFα) dosage | Determination of TNFα plasma concentration (pg/ml) (a biomarker of inflammation and oxidative stress) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma InterCellular Adhesion Molecule 1 (ICAM-1) dosage | Determination of ICAM-1 plasma concentration (ng/ml) (a biomarker of endothelial activation) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma E-Selectine dosage | Determination of E-Selectine plasma concentration (ng/ml) (a biomarker of endothelial activation) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Transcriptome Sequencing of Peripheral Blood Mononuclear Cells | Transcriptomic Analysis to quantify sets of genes involved in endothelial activation, oxidative stress, inflammation and cytokine expression between T-90 min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Metabolome Sequencing of Plasma | Untargeted Metabolomics to identify and quantify molecules involved in endothelial activation, oxidative stress, inflammation and cytokine expression between T-90 min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma Glucose dosage | Determination of glucose plasma concentration (mg/dl) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma triglycerides dosage | Determination of triglycerides plasma concentration (mg/dl) between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Plasma insulin dosage | Determination of insulin plasma concentration (pmol/L) between T-90min to T360min | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| blood Peripheral Blood Mononuclear Cells (PBMC) count | Determination of PBMC count (/mm3) and phenotyping between T-90min to T360min. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| PBMC production of Reactive Oxygen Species (ROS) | Assessment of the ROS level (between T-90min to T360min) produced by isolated PBMC following oxidative stress induction. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| Questionnaire of acceptability | Acceptability was assessed by a 9-point time scale where "1" means a very poor acceptability and "9" means a very good acceptability. | Day 0 (V1), Day 28 (V2), Day 56 (V3). |
| ID | Term |
|---|---|
| D024821 | Metabolic Syndrome |
| ID | Term |
|---|---|
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D014674 | Plant Proteins, Dietary |
| D007930 | Leucine |
| D001120 | Arginine |
| D000080224 | Animal Proteins, Dietary |
| ID | Term |
|---|---|
| D004044 | Dietary Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D010940 | Plant Proteins |
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
| D019602 | Food and Beverages |
| D000597 | Amino Acids, Branched-Chain |
| D000596 | Amino Acids |
| D000601 | Amino Acids, Essential |
| D024361 | Amino Acids, Basic |
| D000599 | Amino Acids, Diamino |
Not provided
Not provided